Glucotrack (GCTK) shares surged over 69% in after-hours trading following the U.S. Patent and Trademark Office issuing a Notice of Allowance for a patent related to its continuous blood glucose monitoring (CBGM) platform. This patent strengthens intellectual property protection for their implantable glucose monitoring systems, which is a key strategic move for the company.
Glucotrack (GCTK) experienced a significant overnight spike due to the announcement of a patent allowance for its continuous blood glucose monitoring (CBGM) technology. This patent strengthens the company's intellectual property around its novel implantable glucose monitoring systems, which is crucial for a medical technology firm. This development is a positive catalyst for GCTK, as it validates their technology and provides a competitive advantage, potentially attracting investor interest and supporting future commercialization efforts. While the stock has been trading near its 52-week low and has a negative price trend, this news could signal a potential turning point, offering a short-term trading opportunity for those looking to capitalize on the patent news and long-term potential for investors if clinical trials progress successfully.